[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hepatoblastoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":103,"states":104},"Hepatoblastoma",15,14,[8,16,23,29,35,41,47,53,59,66,72,78,84,90,96],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04928677","A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment",[12],"Phase 1","RECRUITING","2026-08-26T02:18:49.989941Z","2026-05-05T02:43:27.169252Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04634357","ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma",[20],"Phase 1\u002FPhase 2","2026-08-26T02:17:21.315591Z","2026-07-19T19:36:05.119597Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06941272","A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C\u002FLIGHTBEAM-U01)",[20],"2026-08-26T02:16:28.221034Z","2026-07-19T19:36:05.059044Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06198296","Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells",[12],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:29.711287Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07148050","Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells",[12],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:29.698343Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT04851119","Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors",[20],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:29.139986Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT04308330","Vorinostat in Combination With Chemotherapy in Relapsed\u002FRefractory Solid Tumors and CNS Malignancies",[12],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:28.511395Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT04897321","B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",[12],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.511090Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":64,"content_modified":65},"NCT01804634","Reduced Intensity Haploidentical BMT for High Risk Solid Tumors",[63],"Phase 2","2026-08-26T02:15:50.539717Z","2026-05-05T02:43:27.448232Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT04901702","Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma",[20],"2026-08-26T02:18:32.765187Z","2026-05-05T02:35:31.688370Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT04199741","PET\u002FCT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56",[20],"2026-08-26T02:18:04.640417Z","2026-07-05T05:32:16.773657Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06235125","Safety and Feasibility of Intraoperative Visualization With Cytalux in Children",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.069602Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT05556642","Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative",[],"2026-08-26T02:15:28.524219Z","2026-05-13T02:55:06.362594Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT03959800","Molecular Basis of Pediatric Liver Cancer",[],"2026-08-26T02:19:11.399072Z","2026-05-13T02:55:06.181246Z",{"nct_id":97,"title":98,"phases":99,"status":100,"updated_at":101,"content_modified":102},"NCT04337177","Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:02:58.488119Z","2026-05-05T02:43:28.743177Z",[],[105,109,112,116,119,122,125,128,132,135,138],{"state":106,"count":107,"slug":108},"California",6,"california",{"state":110,"count":107,"slug":111},"New York","new-york",{"state":113,"count":114,"slug":115},"Georgia",4,"georgia",{"state":117,"count":114,"slug":118},"Massachusetts","massachusetts",{"state":120,"count":114,"slug":121},"Ohio","ohio",{"state":123,"count":114,"slug":124},"Tennessee","tennessee",{"state":126,"count":114,"slug":127},"Texas","texas",{"state":129,"count":130,"slug":131},"Colorado",3,"colorado",{"state":133,"count":130,"slug":134},"District of Columbia","district-of-columbia",{"state":136,"count":130,"slug":137},"Missouri","missouri",{"state":139,"count":130,"slug":140},"Pennsylvania","pennsylvania"]